Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues
Open Access
- 14 July 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (7), 672
- https://doi.org/10.3390/ph14070672
Abstract
Site-specific antibody conjugations generate homogeneous antibody-drug conjugates with high therapeutic index. However, there are limited examples for producing the site-specific conjugates with a drug-to-antibody ratio (DAR) greater than two, especially using engineered cysteines. Based on available Fc structures, we designed and introduced free cysteine residues into various antibody CH2 and CH3 regions to explore and expand this technology. The mutants were generated using site-directed mutagenesis with good yield and properties. Conjugation efficiency and selectivity were screened using PEGylation. The top single cysteine mutants were then selected and combined as double cysteine mutants for expression and further investigation. Thirty-six out of thirty-eight double cysteine mutants display comparable expression with low aggregation similar to the wild-type antibody. PEGylation screening identified seventeen double cysteine mutants with good conjugatability and high selectivity. PEGylation was demonstrated to be a valuable and efficient approach for quickly screening mutants for high selectivity as well as conjugation efficiency. Our work demonstrated the feasibility of generating antibody conjugates with a DAR greater than 3.4 and high site-selectivity using THIOMABTM method. The top single or double cysteine mutants identified can potentially be applied to site-specific antibody conjugation of cytotoxin or other therapeutic agents as a next generation conjugation strategy.Keywords
This publication has 53 references indexed in Scilit:
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsProceedings of the National Academy of Sciences of the United States of America, 2012
- Site-specific chemical protein conjugation using genetically encoded aldehyde tagsNature Protocols, 2012
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesNature Biotechnology, 2012
- Analytical methods for physicochemical characterization of antibody drug conjugatesmAbs, 2011
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast CancerClinical Cancer Research, 2010
- Design and Application of Antibody Cysteine VariantsBioconjugate Chemistry, 2010
- Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tagProceedings of the National Academy of Sciences of the United States of America, 2009
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Efficient Site-Specific Labeling of Proteins via CysteinesBioconjugate Chemistry, 2008
- Site-specific Conjugation on Serine → Cysteine Variant Monoclonal AntibodiesOnline Journal of Public Health Informatics, 2000